Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 7/20 | 0.43 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | APLNR | P35414 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | USP1 | O94782 | 1/20 | 0.38 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4992007 | 0.87 | EGLN3 (0.40) | CCR9EGLN3MEN1KMT2APOLB | |
| SCHEMBL4739209 | 0.86 | EGLN3 (0.46) | CCR9EGLN3MEN1KMT2APOLB | |
| SCHEMBL4739981 | 0.85 | EGLN3 (0.56) | CCR9EGLN3MEN1KMT2APOLB | |
| SCHEMBL4741832 | 0.84 | CCR9 (0.44) | CCR9EGLN3MEN1KMT2APOLB | |
| SCHEMBL4737534 | 0.84 | EGLN3 (0.44) | CCR9EGLN3MEN1KMT2APOLB | |
| SCHEMBL4741831 | 0.82 | EGLN3 (0.48) | CCR9EGLN3MEN1KMT2A | |
| SCHEMBL4740088 | 0.81 | CCR9 (0.45) | CCR9EGLN3MEN1KMT2ATP53 | |
| SCHEMBL5000326 | 0.81 | CCR9 (0.47) | CCR9EGLN3MEN1KMT2ATP53 | |
| SCHEMBL4740335 | 0.80 | EGLN3 (0.46) | CCR9EGLN3MEN1KMT2A | |
| SCHEMBL4737518 | 0.79 | EGLN3 (0.51) | CCR9EGLN3MEN1KMT2ACCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008089051-A1 | N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | CCR9 4560/4885EGLN3 3/4885MEN1 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.